New drug shows promise in preventing transplant complication
NCT ID NCT03207958
First seen Apr 24, 2026 · Last updated May 19, 2026 · Updated 1 time
Summary
This small pilot study tested whether the drug belimumab (Benlysta) could safely prevent chronic graft-versus-host disease (GvHD) in 10 adults who had a stem cell transplant for blood cancer. Chronic GvHD is a serious condition where donor immune cells attack the patient's body. The study focused on safety and early signs of effectiveness, finding that belimumab was generally well tolerated and may help reduce GvHD severity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.